Edition:
United Kingdom

Profile: Acer Therapeutics Inc (ACER.OQ)

ACER.OQ on NASDAQ Stock Exchange Capital Market

19.12USD
17 May 2019
Change (% chg)

-- (--)
Prev Close
$19.12
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
11,886
52-wk High
$34.10
52-wk Low
$16.32

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., incorporated on March 15, 1991, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States.

The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).

Company Address

Acer Therapeutics Inc

One Gateway Center (300 Washingt
Suite 351
NEWTON   MA   02458
F: +1302.6555049

Company Web Links